BC847B/215
Nexperia USA Inc.
The Nexperia USA Inc. BC847B/215 is a bipolar transistor. It is RoHS3 Compliant and has an MSL Level 1 rating.
| Distributor | Stock | Pricing | MOQ | PKG | Lead Time | Date Code | On Order Quantity | On Order Delivery | |
|---|---|---|---|---|---|---|---|---|---|
|
1,150 pcs
|
1150 pcs | On Request | 1 | On Request | On Request | 2026-02-25 06:16:38 | On Request | On Request |
| Category | |
| Manufacturer Name | |
| SVHC Present |
DTX-101 is an AAV based gene therapy developed by MEPCO. It functions as a factor IX stimulant, activating the blood coagulation pathway.
This therapy is indicated for congenital disorders, hemic and lymphatic diseases, and other diseases, specifically targeting Hemophilia B. The highest phase it reached was Discontinued Phase 1/2.
Compliance information indicates it is RoHS3 Compliant, has a Moisture Sensitivity Level (MSL) of 1 Unlimited, and is REACH Unaffected.
| Qty | Low | High |
|---|---|---|
| 1+ | $1.20 | $1.20 |
Estimated market price range - modelled values for guidance only, not live distributor offers.
DTX-101 is RoHS3 Compliant.
The MSL for DTX-101 is Level 1.
DTX-101 is REACH Unaffected.
DTX-101 is used for Hemophilia B, congenital disorders, and hemic and lymphatic diseases.
DTX-101 acts as a factor IX stimulant, activating the blood coagulation pathway.